AstraZeneca Pharma gets Import, Market permission in Form CT-20 from DCGI for Olaparib Film-Coated tablets

20 Aug 2022 Evaluate

AstraZeneca Pharma India has received Import and Market permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India (DCGI) for Olaparib Film-Coated tablets 100 mg and 150 mg - additional indication.

Through this approval, Olaparib Film-Coated tablets 100 mg and 150 mg is additionally indicated as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy.The receipt of this permission paves way for the launch of Olaparib Film-Coated Tablets 100 mg and 150 mg (Lynparza) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma I Share Price

5250.00 -8.30 (-0.16%)
13-May-2024 15:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1530.00
Dr. Reddys Lab 5913.95
Cipla 1421.00
Zydus Lifesciences 993.40
Lupin 1684.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.